Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma gets...

    Aurobindo Pharma gets final USFDA nod for dementia drug

    Written by savita thakur thakur Published On 2016-03-30T11:09:33+05:30  |  Updated On 30 March 2016 11:09 AM IST
    Aurobindo Pharma gets final USFDA nod for dementia drug

    New Delhi : Drug firm Aurobindo Pharma BSE -2.11 % has received final approval from USFDA to manufacture and market Rivastigmine Tartrate Capsules USP, used for the treatment of dementia disease, in the American market.


    "The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg," Aurobindo Pharma said in a BSE filing.


    The company said this product is expected to be launched in the first quarter of next fiscal.


    The approved product is bioequivalent and therapeutically equivalent to Novartis Pharmaceuticals Corporation's Exelon Capsules, it added.


    According to IMS, the approved product has an estimated market size of USD 26.7 million for the twelve months ending January 2016, Aurobindo Pharma said.


    Exelon is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease.





    Aurobindo Pharma currently has a total of 246 ANDA approvals (211 final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from the US.
    Aurobindo Pharma shares were trading 3.58 per cent lower at Rs 719 apiece during late morning session on BSE.



    Alzheimer'sANDAAurobindodementiadementia diseaseNovartisParkinson'sRivastigmine Tartrate CapsulesUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok